Statement: both primary clinical trial and secondary clinical trial document incidences of cardiac adverse effects or infectious complications
Primary_evidence: Adverse Events 1:   Total: 0/655 (0.00%) Adverse Events 2:   Total: 0/580 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 0/15 (0.00%) Adverse Events 2:   Total: 0/16 (0.00%)